THE DIABETIC FOOT: TREATMENT
Dr. S.M.Sadikot ( Mumbai ) Consultant in Endocrinology,
Diabetes and Metabolic Disorders, Jaslok Hospital and Research Centre,
Mumbai.
Introduction
Foot problems in a person with diabetes are one of the most
common complications seen in India. Although intensive efforts need to be
made to avoid these foot complications, it is more easily said than done,
especially in our country where walking barefoot is much more common than
in the West. The reality is such that often the presenting complaint of a
person with diabetes is a major foot infection, often with non healing
ulceration. The morbidity, and sometimes, the mortality, associated with
these complications are immemnse not only from the purely medical
viewpoint, but also from the socioeconomic and psychological aspects. In
fact, it has been shown that after accidents, diabetes associated foot
problems are the secong most common cause of lower limb amputations in
India. Patients with diabetes mellitus may present to the diabetes
mellitus may present to the primary care practitioner with dangerous
lower-extremity sequelae that are extremely challenging to treat. The high
incidence of amputation in this patient population is, line large part,
the result of uncontrolled infection and ulceration of the foot.
Cellulitis
All diabetic patients are prone to
developing infections of the foot . Once established, these infections are
more severe and more treatment - refractory than in nondiabetics. If left
unchecked these infection may progress to cellulitis.
Pathogenesis
Foot infection in diabetics develops because of coexisting
angiopathy, immunopathy, and neuropathy. Angiopathy begins at the
microvascular level, with thickening of the basement membrane and reduced
blood flow. This often leads to platelet aggregation and a further
decrease in perfusion and oxygenation of foot tissues, together with
reduced chemotaxis of neutrophils, macrophages, and other protentially
protective cells. Immunopathy is the result of prolonged periods of
hyperglycemia, which reduce the ability of these cells to phagocytize
bacteria.
Neuropathy impairs the structural integrity of the foot
while decreasing the perception of injury. Bacteria gain access via open
wounds, including fissures and punctures in the insensate foot. However ,
many diabetic patients who present with a cellulitic foot do not have an
obvious open wound, cellulitis may be the result of hematogenous bacterial
spread from a urinary or respiratory tract infection to which diabetics
are also susceptible. these patients present with the cardinal signs of
infection - erythema, edema, and calor.
Causative
pathogens
The causative pathogens are varied and can range from
aerobic organisms such as Staphylococcus aureus, group B Streptococcus,
Enterococcus, Coagulase-negative Staphylococcus, Proteus mirabilis,
Proteus vulgaris, Enterbacter, Citrabacter, and Serratia. Pseudomonas has
also been isolated from diabetic foot infections secondary to long -
standing open ulcerations. In addition , anaerobic organisms such as
Bactericides, Peptococcus, and peptostreptococcus are often
identified.
Infection with several organisms is common. One should
therefore perform both aerobic and anaerobic cultures, from sample
material taken from the deeper parts of the wound.
TREATING CELLULITIS
Empiric Antibiotic
therapy
Because of the frequency of polymicrobial involvement
empiric treatment should cover Gram- negative aerobic as well as an
aerobic organisms. The antibiotic chosen should be bactericiadal as
opposed to beacteriostatic. In general, bacteriostatic antibiotics require
an intact immune system to function properly.
Mild or Moderate
Infections
Treat mild infections with broad - spectrum oral
antibiotics such as amoxicillin/clavulanic acid, clindamycin, cefuroxime
axetil, or cephalexin. This can be done on an outpatient basis. It is not
necessary to culture superficial diabetic wounds. Moderate infection
require treatment with intravenous antibiotics on an impatient basis.
Broad - spectrum antibiotics such as
imipicillin/sulbactam,piperacillin/tazobactam,ticarcillin/clavulanic acid,
clindamycin or a fluoropuinolone should provide adequate coverage.
Although clindamycin is a bacteriostatic antibiotic, its antibacterial
activity has been shown to be bacteriocidal at higher dose concentrations.
The newer third - and fourth - generation fluoroquinolones, some not yet
widely available in India,-levefloxacin, grepafloxacin, sparfloxacin, and
trovafloxacin - are particularly effective against polymicrobial
infections.
Abscesses
After 2 to
3 days of antibiotic therapy, cellulitis often localizes to one area of
the foot resulting in the formation of an abscess. Proper management of
the abscess entails incision and drainage. In addition,obtain deep
specimens intraoperatively for culture and sensitivity testing. These
abscesses are often polymicrobial and filled with many contaminants. After
removing all necrotics debris , irrigate the wound with normal sterile
saline using a power irrigation pulse lavage system, which will enable you
to dilute the concentration of invading bacteria. A bacterial count of at
least 105 per mm3 of soft tissue will establish an
infection; therefore , dilution of bacteria in infected tissue is an
essential adjunct to infection control.
Severe
Infections
Severe infections (which are all life threatening
)are characterized by massive cellulitis with ascending lymphangitis. The
patient is likely to have sepsis, fever, and a significantly elevated
white blood cell count. Narcotizing facetious with liquefaction necrosis
and gas formation in the soft tissues may also be present. The antibiotic
of choice is imipenem/cilastatin. However, ampicillin/sulbactam has proved
effective in treating limb-threatening infections Synergistic antibiotic
therapy including third - or - fourth - generation cephalosporin,
ticarcillin/clavulanic acid, piperacillin/tazobactam, imipenem, or
meropenem, each together with an aminoplycoside, are also effective
attaints limb threatening infections.
In addition, one should seek
surgical consultation for wide incision and drainage, debridement, and
possibly, for ablative open guillotine amputation as a life-saving
measure.
In investigating the different treatment options for foot
infections in patients with diabetes without systemic infection, one study
has found that the least expensive approach was prolonged treatment with
oral antibiotics following initial hospitalization for surgical
debridement; the most expensive approach was immediate amputation. A
second study has found that debridement and , if indication ,
revascularization, resulted in long - term salvage of threatened feet,
even in high - risk patients even with gangrene. A third study has found
that early amputation in patients with foot infections who were not
candidates for arteroa; reconstruction permitted early rehabilitation,
decreased long - term morbidity, and reduced overall
cost.
Ulceration's
Diabetic foot ulceration's will heal under four conditions-
adequate peripheral perfusion, control of infection, off-loading of
pressure-sensitive or ulcerated areas, and control of diabetes, including
concurrent systemic diseases. off - loading the wound can be accomplished
externally or internally. Shoe modification padding, debridement of
surrounding hyperkeratotic tissue , and total contact casting are forms of
external off-loading. Bunionectomy, hammer toe correction, metatarsal head
resection, and other exostosectomies are means of off-loading internally .
If the diabetic patient has adequate peripheral perfusion and is stable,
surgical removal of pressure areas can accelerate ulcer
healing.
Wagner Ulcer Grade
Classification
| Grade |
Wound Characteristics |
| 0 |
Pre-ulcerative lesions, healed ulcers, presence of
bony deformity |
| 1 |
Superficial ulcer without subcutaneous tissue
involvement |
| 2 |
Penetration through the subcutaneous tissue; may
expose bone, tendon, ligament of joint capsule |
| 3 |
Osteitis, abscess, or osteomyelitis |
| 4 |
Gangrene of digit |
| 5 |
Gangrene of foot requiring
disarticulation |
Various classification schemes
have been devised to aid in the diagnosis treatment, and prognosis of
ulceration's. The most valuable scheme to be the one developed in 1981 by
F. William Wagner. This scheme is based on the depth of the lesion and
involves six stages ranging from no ulcer to gangrene of the entire foot.
Wagner's scheme serves three very important purposes: to help standardize
treatment plans; to help standardize treatment plans; to increase the
level of communication between practitioners caring for the same patient;
and to identify positive and negative changes in the progress of treatment
Grade O
The treatment of Wagner grade ) lesions -
prominent osseous structures (e.g., bunions, hammer toes) and calluses -
mainly involves prevention. For example, if a callus has formed because of
abnormal stress on an area of the foot, remove the source of stress by
padding the shoes or by recommending better- fitting shoes . In some cases
, it may be beneficial to debride the callus as well. DeBridement serves
to offload the area and permit identification of any ulceration under the
callus that might have gone unnoticed. Padding the shoes is also
recommended if a significant bony prominence is present without a callus.
The main goal is to prevent the progression of a grade ) lesion to the
status of a superficial ulcer.
Grade 1
These are
superficial ulcers, which often have a base of necrotic tissue. The
chronic neuropathic ulcer matrix is hypoxic, acidic and hypoglycemic.
Attempted healing via smooth muscle myofibril contraction is often
inadequate to close the wound. Necrotic tissue that is present both
inhibits epithelialization and provides a culture medium for bacterial
growth ; thus , it is impotent to debride the wound. The purpose of
debridement is to convert the chronic would matrix into an acute wound.
Matrix by removing necrotic debris, bacteria and surrounding
hyperderatitic tissue. Aggressive sharp debridement provides a good
granular, bleeding bed at the base of the wound which permits an influx of
platelets and platelet - derived growth factors needed for healing .
Debridement should be performed on a weekly basis until healing is
complete.
Wet - to - dry dressings (soaked in saline but allowed to
dry before removal) applied every 6 to 8 hours provide a moist environment
for the wound to heal . Once the dressing dries , removal serves the
function of debridement by eliminating any necrotic tissue adhering to the
bandage. One now implements wet-to-moist dressing changes because we
believe that removal of the dry dressings tends to damage the wound ,
impairing reepithelialization by inhibiting retye peg formation the
subsequent epidermis is fragile and easily damaged which results in a high
recurrence of locer formation the patient should perform wet-to-moist
dressing changes once or twice daily. (Wet-to-dry dressing changes should
be done once a day.)
In addition to aggressive debridement and
wet-to-moist dressing changes, one can apply a new topical gel to diabetic
wounds. Becaplermin 0.1% is a recombinant endogenous human
platelet-derived protein growth factor(PDGF-BB) gel that has a
chemoattractant effect on local and surrounding undifferentiated
mesenchymal cells recruiting fibroblasts and inflammatory and smooth
muscle cells. It is indicated for the treatment of diabetic neuropathy
rekated lower-extremity ulcers that extend into the subcutaneous tissue or
beyond and have an adequate blood supply. The PDGF binds with the alpha
receptor sites found in the acute wound matrix. Therefore, initial wide
debridement of a nonhealing diabetic foot ulcer is recommended to convert
the chronic wound matrix into an acute wound matrix exposing a significant
number of these alpha receptor sites. With the application of becaplermin
routine debridement of the ulcer on subsequent office visits is
discouraged, as that tends to disrupt these receptor sites, thereby
decreasing the effectiveness of PDGF. Debridement of the hyperkeratotic
periphery of the ulcer is recommended to off-load undue pressure on the
surrounding skin. If significant necrotic or fibrous tissue redevelops
during the course of PDGF treatment, intermittent wide debridement by a
qualified have shown that the combination of good wound care - aggressive
debridement , infection control and pressure relief - and the application
of becaplermin gel increase the rate of wound healing .
Grade
2
These are deepulcers that extend toligaments , tendons ,
muscle, and / or bone . Treatment is essentially the same as that for
grade 1 ulcer . The main emphasis is on prevention of infection, which may
necessitate amputation . Some patients with grade2 ulceration's require
aggressive debridement in an operating room setting.
Grade
3
These deep ulcers are marked by abscess formation cellutlitis
, osteomyelitis, and /or tendinitis. They require a more aggressive form
of treatment. A new class of antiniotis , which works by attacking the
bacterial cell's membrane has been developed . The first antibiotic in
this class , the topical gel pexiganan acetate, is currently being studied
for the treatment of diabetic foot ulcers. The result look promising. If
clinical signs and plain x-rays suggest ostemoyelitis, order a 3 phase
technetium bone scan. Technetium-labelled white blood cell bone scan are
specific for osteomyelitis and can confirm the diagnosis when other
osseous abnormalities cannot be ruled out. Once the diagnosis of
osteomyelitis is confirmed, the treatment usually entails surgical
excision of all infected bone and tissue . It is often necessary to
amputate digits and / or remove portions of the metatarsals. In cases with
minimal bone involvement , a 6 week course of intravenous antibiotics is
recommended.
Grade 4
These deep lesions involve
gangrene of any part of the forefoot. When one deals with gangrenous
changes, the main goal is to prevent "wet "gangrene from developing . A
combination of gangrenous changes, deep infection and gas in the tissues
almost always spreads rapidly up the leg (narcotizing fascists).
Amputation of all gangrenous and infected tissue is the treatment of
choice
Grade 5
These deep lesions involve gangrenous
changes in the rearfoot or the entire foot. They often require below the
knee amputation.
Another classification which has been
seen to be of significant value in the valuation and management of the
diabetic foot is The University of Texas Diabetic Foot
Classification.
The University of Texas Diabetic Foot
Classification System
| Category 0
No Pathology |
Category 1
Neuropathy, No Deformity |
Category 2a
Neuropathy with Deformity |
Category 3a
History of Pathology |
| Patient diagnosed with diabetes mellitus |
Protective sensation absent by Semmes
Weinstein test |
Protective sensation absent |
Protective sensation absent |
| Protective sensation intact by Semmes
Weinstein test |
ABI > 0.8 and toe systolic pressure > 45
mm Hg |
ABI > 0.8 and toe systolic pressure > 45
mm Hg |
ABI > 0.8 and toe systolic pressure > 45
mm Hg |
| Ankle-brachial index (ABI) > 0.08 and toe
brachial index > 0.45 mm Hg |
No history of ulceration |
History of neuropathic ulceration |
No history of neuropathic ulceration |
| Foot deformity may be present |
No history of Charcot's joint |
No history of Charcot's joint |
History of Charcot's joint |
| No history of ulceration |
No foot deformity |
Foot deformity present |
Foot deformity present |
| Possible Treatment
Shoe accommodations
Patient education
Follow up 6 to 12 months |
Possible Treatment
Same as category 0 plus:
Possible shoe gear accommodation
Quarterly visits to assess shoe gear and monitor for signs
of irritation
Follow up 3 to 4 months |
Possible Treatment
Same as category 1 plus:
Pedorthist/orthotist consultation for possible
custom-molded/ extra-depth shoe accommodation
Possible prophylactic surgery to alleviate foot deformity
Follow up 2 to 3 months |
Possible Treatment
Same as category 2 plus:
Pedorthist/orthotist consultation for possible
custom-molded/ extra-depth shoe accommodation
Possible prophylactic surgery to alleviate foot deformity
More frequent visits may be indicated for monitoring
Follow up 1 to 2 months |
| Category 4A
Neuropathic Wound |
Category 4B
Acute Charcot's Foot |
Category 5
The Infected Diabetic Foot |
Category 6
The Ischemic Limb |
| Protective sensation absent |
Protective sensation absent |
Protective sensation may be present |
Protective sensation may not be
present |
| ABI > 0.8 and toe systolic pressure > 45
mm Hg |
Hg ABI > 0.8 and toe systolic pressure >
45 mm Hg |
Infected wound |
ABI < 0.8 or toe systolic pressure < 45
mm Hg or pedal transcutaneous oxygen present tension < 40
mm Hgtension < 40 mm Hg |
| Foot deformity normally present |
Non-infected neuropathic ulcer may be
present |
Charcot's joint may be present |
Ulceration may be present |
| No Charcot's joint present |
Charcot's joint present |
Possible Treatment
Debridement of infected, necrotic tissue and/or bone as
indicated
Possible hospitalization, institute antibiotic regimen
Medical management |
Possible Treatment
Vascular consult, possible revascularization
If infection present, treat as in Category 5. Vascular
consultation with control of sepsis |
| Possible Treatment
Same as category 3 plus:
Pressure reduction program instituted
Wound care program instituted |
Possible Treatment
Same as category 3 plus:
Pressure reduction program instituted
Thermometric and radiographic monitoring
If ulcer present, same treatment as category 4A
| |
Recent Advances in Treatments for Diabetic Foot
Ulceration
The moist wound healing concept is widely accepted in treating DFUs.
Some of the benefits of this approach include prevention of tissue
dehydration and cell death, acceleration of angiogenesis, and facilitating
the interaction of growth factors with the target cells. The standard of
care recommended by the American Diabetes Association is saline-moistened
gauze. The "wet-to-dry" concept is no longer acceptable because if the
gauze becomes dry before the next dressing change, it may cause damage to
the wound bed and disrupt the healing process. Hydrocolloid dressings and
hydrogels can maintain the moist wound environment while providing some
autolytic debridement. Enzymatic debridement agents can be helpful for
necrotic tissues. The alginates and absorptive dressings absorb drainage
well and maintain moist wound environments. Other dressings are
impregnated with collagen, zinc, or other factors that stimulate wound
healing. Some dressings have a coated antimicrobial barrier. Composite
dressings have more than one characteristic promoting wound healing.
Contact-layer dressings prevent damage to the wound bed. Foam dressings
may provide some padding in addition to absorbency. There have been no
large, controlled studies to show the efficacy of hyperbaric oxygen
therapy and electrical stimulation on DFUs.
Becaplermin gel is a platelet-derived growth factor (PDGF) of
recombinant human origin. PDGF stimulates and recruits macrophages,
neutrophils, and fibroblasts; stimulates angiogenesis; and stimulates
granulation tissue formation, wound contraction, and wound remodeling.
Becaplermin gel should be used in wounds that have adequate blood supply
and a clean wound bed (one without infection or necrosis). When used in
conjunction with appropriate wound care, becaplermin gel has been shown to
increase the incidence of complete wound closure (50% versus 35% for
placebo) and decrease the time to complete wound closure (86 versus 127
days).
The amount of becaplermin gel applied varies by wound size (see Table
1). The amount should be measured out onto a clean surface and the gel
applied using an application aid (Q-tip, etc.) to a thickness of 1/16
inch. The gel should be covered with a saline-moistened gauze pad and left
in place for 12 hours. After 12 hours, remove the gauze, rinse the ulcer
with saline, and apply a new moistened dressing (without becaplermin gel)
for the remaining 12 hours. Repeat this application process once
daily.
In inches
- Measure the greatest length and width of ulcer in inches.
- Calculate the length of gel (in inches) required from a 15
gram tube by multiplying the length x width x 0.6.
- Each square inch of ulcer surface requires approximately
2/3-in. length of of gel.
|
In centimeters
- Measure the greatest length and width of the ulcer in
centimeters.
- Calculate length of gel that should be squeezed from a 15
gram tube by multiplying the length x width divided by 4.
- Each square centimeter of ulcer surface requires
approximately 0.25-centimeter length of gel.
|
Living skin equivalent (LSE) products are the newest technological
advances for diabetic foot ulcers. One LSE product consists of dermal
fibroblasts cultured in vitro onto a bioabsorbable mesh to
produce a metabolically active tissue that has histological
characteristics similar to the dermal papillary of newborn skin. The first
large prospective study showed some promising results; another study is
underway.
Another available LSE product resembles living human skin in that it
consists of two primary layers: an epidermis and a dermis. The
well-differentiated epidermal layer includes a protective stratum corneum
formed from human living keratinocytes. The dermal layer is composed of
living human fibroblasts dispersed in a bovine collagen matrix. The
keratinocytes and fibroblasts are cultivated from human infant foreskin. A
prospective, randomized, controlled, clinical trial was performed to
evaluate the safety and efficacy of this LSE in the treatment of diabetic
foot ulcers. The result from a single center revealed that this LSE
significantly healed more ulcers (75% vs. 41% wound healing in 12 weeks)
and in less time (38.5 days vs. 91 days) compared to standard treatment
alone. The multi-center result showed similar efficacy; 56 percent of
ulcers treated with the LSE healed within 12 weeks compared to 38 percent
for standard treatment alone, with complete healing achieved on the
average of 65 days compared to 90 days. The LSE was not associated with
any significant side effects when compared to standard care alone.
Recently, the FDA has approved this LSE for use in treatment of diabetic
foot ulcers.
The skin equivalent used in the study is a bilayered, living human skin
analog that consists of both a dermal and epidermal layer. The dermis is
made from human cultured fibroblasts (from donated neonatal foreskin) and
purified bovine collagen. The epidermis consists of keratinocytes that are
also derived from the neonatal foreskin. Compared to normal skin, the skin
equivalent is devoid of major immunogenic components, resulting in a lack
of immunological response and rejection reaction when applied in human
wounds. Application of the skin equivalent may stimulate healing through
the action of cytokines and other matrix components that stimulate
epithelialization from the edge of the wound and promote the formation of
new skin at the applied area, resulting in frank graft take which leads to
a graft integration similar to the one observed autologous skin
grafting.
Bioengineered tissue has been shown in one report to heal statistically
significantly more wounds than control treatment (50.8% versus 31.7%)
after 12 weeks of therapy.[24] Currently,
there are two bioengineered tissue products, Apligraf and Dermagraft.
Apligraf is approved by the Food and Drug Administration for treatment of
skin ulcers caused by venous insufficiency, and recently received FDA
approval for treatment of diabetic foot ulcers when other traditional
treatments have failed. Dermagraft is not currently marketed in the United
States.
Modern technology has led to an explosion of new wound dressings,
topical products, and living skin equivalents in the last few years. All
new techniques and products should be rigorously tested for safety and
efficacy before patient application or use. The studies and clinical
trials involving these devices and products should be prospective,
randomized, and well controlled. The results of studies should be compared
to accepted gold standards or to clearly defined measurements. The
conclusions drawn from the studies should be supported by the results.
Inspite of all these advances, extensive debridement of the ulcer area,
intensive treatment of the infection, abolition or significant reduction
of the trauma related to weight-bearing at the ulcer area, and adequate
restoration of the blood flow, when required, are absolute prerequisites
for successful wound healing and cannot be replaced by any new therapeutic
intervention, including the application of living human skin equivalents.
One Protocol which we have found quite useful is given below as a flow
chart
Conclusion
Foot problems in a person with diabetes can
have disastrous consequences. Though recent advances in the management of
these problems have increased our abilities to save the lower limb, the
best management still remains prevention. This can only follow with
intense patient education about foot care and a proactive role in treating
the factors which lead to these foot problems.
Even if foot problems do occur, they
must be recognised early and prompt and rigorous treatment at this stage
can go a long way to prevent the more serious sequelae.
Your Feedback Please
Recommended Reading |